M3 Wealth Management LLC Acquires Shares of 23,777 Pfizer Inc. $PFE

M3 Wealth Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 23,777 shares of the biopharmaceutical company’s stock, valued at approximately $592,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Franklin Resources Inc. boosted its position in shares of Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. Neuberger Berman Group LLC boosted its position in shares of Pfizer by 203.8% during the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after purchasing an additional 6,045,763 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Pfizer by 120.9% during the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock worth $230,986,000 after purchasing an additional 5,202,884 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 0.2%

PFE opened at $25.86 on Wednesday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 12 month low of $23.06 and a 12 month high of $28.75. The firm’s fifty day simple moving average is $26.82 and its 200 day simple moving average is $26.26. The stock has a market capitalization of $147.39 billion, a P/E ratio of 19.74 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the previous year, the business earned $0.92 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s payout ratio is presently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Several recent articles highlight bullish arguments for Pfizer, including analyst optimism around late-stage pipeline assets and the view that the stock could still have meaningful upside if upcoming drug trials and launches deliver. Article Title
• Positive Sentiment: Coverage also points to Pfizer’s attractive dividend yield and argues the payout remains supported, which may appeal to income-focused investors even while growth is uneven. Article Title
• Positive Sentiment: An article on Pfizer’s abrocitinib atopic dermatitis study nearing a data milestone suggests a near-term catalyst that could improve sentiment if results are favorable. Article Title
• Neutral Sentiment: One piece frames Pfizer as a “best medical stock” idea based on billionaire interest, but that is more of a screening-style thesis than a direct new company-specific catalyst. Article Title
• Neutral Sentiment: Another article says Pfizer’s investment narrative is shifting, with fair value estimates and analyst targets reflecting both pipeline hopes and revenue concerns, indicating a split Wall Street view rather than a clear breakthrough. Article Title
• Negative Sentiment: The biggest headwind is the Eliquis patent cliff, with projected multi-year revenue losses that could weigh on Pfizer’s future sales and earnings if new products do not offset the decline. Article Title

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Guggenheim lifted their price target on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. UBS Group boosted their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research report on Monday, April 13th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.61.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.